Search

Displaying results 11 - 20 of 303 in total
  1. Drug

    Docaravimab

    go.drugbank.com/drugs/DB17802
    Experimental

    Synonyms: Immunoglobulin g2b-kappa, anti-(rabies virus strainera (evelyn-rockitniki-abelseth) glycoprotein ectodomain epitope g-iii), mus musculus monoclonal antibody
  2. Drug

    Toll-like receptor 9

    go.drugbank.com/drugs/DB15320
    Investigational

    Toll-like receptor 9 is under investigation in clinical trial NCT03007732 (Pembrolizumab in Combination With Intratumoral SD-101 Therapy).

    Synonyms: Toll-like receptor 9Categories: Toll-Like Receptor 9, agonists
  3. Drug

    SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)

    go.drugbank.com/drugs/DB18705
    Approved

    Bimervax is an adjuvanted non-mRNA COVID-19 vaccine utilizing a SARS-CoV-2 recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer.

    Synonyms: SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer – B.1.351-B.1.1.7 strains, SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)
  4. Drug

    Axicabtagene ciloleucel

    go.drugbank.com/drugs/DB13915
    ApprovedInvestigational

    Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy.

    Categories: CD19 Receptor Interactions, CD19-directed Chimeric Antigen ReceptorSynonyms: Autologous T cells transduced with retroviral vector encoding an anti-CD-19 CD28/CD3-zeta chimeric antigen receptor
  5. Drug

    Zanidatamab

    go.drugbank.com/drugs/DB15471
    ApprovedInvestigational

    Zanidatamab is a bispecific antibody that binds two non-overlapping sites of HER2 (ERBB2). It has been investigated for the treatment of HER2-positive solid tumors, including gastroesophageal, colorectal, and biliary tract cancers. In No...

    Synonyms: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODYCategories: HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
  6. Drug

    Ensovibep

    go.drugbank.com/drugs/DB19078
    Investigational

    Ensovibep is under investigation in clinical trial NCT04501978 (ACTIV-3: Therapeutics for Inpatients With COVID-19).

    Synonyms: glycoprotein receptor binding domain-binding), Designed ankyrin repeat protein (synthetic bivalent human albumin-binding) fusion protein with designed ankyrin repeat protein (synthetic trivalent severe acute respiratory syndrome coronavirus 2 spike
  7. Drug

    Chimeric antigen receptor T-cells

    go.drugbank.com/drugs/DB22146
    Investigational

    Chimeric Antigen Receptor T-cells is under investigation in clinical trial NCT05225363 (Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian

    Synonyms: Chimeric Antigen Receptor T-cell, Chimeric antigen receptor T cells
  8. Drug

    PR-15

    go.drugbank.com/drugs/DB06037
    Investigational

    PR-15 is a novel anti-platelet protein with the potential to treat arterial thrombosis occurring during acute coronary syndromes without the bleeding risk associated with existing agents.

    Synonyms: Revacept
  9. Drug

    Spesolimab

    go.drugbank.com/drugs/DB15626
    ApprovedInvestigational

    Spesolimab is an interleukin-36 (IL-36) receptor antagonist.

    Synonyms: Immunoglobulin G1, anti-(human interleukin 36 receptor) (humanized monoclonal BI 655130 gamma1-chain), disulfide with humanized monoclonal BI 655130 kappa-chain, dimerCategories: Interleukin-36 Receptor Antagonist
  10. Drug

    Epidermal Growth Factor Receptor variant III (EGFRvIII) chimeric antigen receptor T cells

    go.drugbank.com/drugs/DB18654
    Investigational

    Synonyms: Epidermal Growth Factor Receptor variant III (EGFRvIII) chimeric antigen receptor T cells, Autologous Chimeric Antigen Receptor (CAR) Modified Recombinant T Cells Targeting EGFRvIII